Role of Interstitial Radiotherapy in the Management of Clinically Organ-Confined Prostate Cancer: The Jury Is Still Out

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 304-315

  D'Amico, Anthony V ^a   Coleman, C Norman ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; FOLLOW UP; HUMAN; INTERSTITIAL RADIATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIOISOTOPE THERAPY; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; BRACHYTHERAPY; HUMANS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0030061159     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.304     Document Type: Review

References (36)

1. Wallner K, Roy J, Zelefsky M, et al: Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation. Int J Radiat Oncol Biol Phys 29:863-867, 1994
2. 125iodine seed implantation in prostate cancer guided by transrectal ultrasound. J Urol 103:283-287, 1983
3. Wallner K, Chiu-Tsao S, Roy J, et al: A new device to stabilize templates for transperineal I-125 implants. Int J Radiat Oncol Biol Phys 20:1075-1077, 1991
4. Scardino PT, Carlton CE: Combined interstitial and external irradiation for prostatic cancer, in Jevadpour N (ed): Principles and Management of Urologic Cancer. Baltimore, MD, Williams & Wilkins, 1983, pp 392-408
5. Whitmore WF: Interstitial I-125 implantation in the management of prostate cancer. Prog Clin Biol Res 153:513-527, 1984
6. Koprowski CD, Berkenstock KG, Borofski AM, et al: External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma. Int J Radiat Oncol Biol Phys 21:955-960, 1991
7. Kuban DA, Anas EM, Schellhammer PF: I-125 interstitial implantation for prostate cancer: What have we learned 10 years later? Cancer 63:2415-2420, 1989
8. Morton JD, Peschel RE: Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. Int J Radiat Oncol Biol Phys 14:1153-1157, 1988
9. 125I seed implantation. J Endourol 4:375-379, 1990
10. Kaye KW, Olson DJ, Lightner DJ, et al: Improved technique for prostate seed-implantation: Combined ultrasound and fluoroscopic guidance. J Endourol 6:61-66, 1992
11. Wallner K, Roy J, Zelefsky M, et al: Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 30:405-409, 1994
12. Priestly JB, Beyer DC: Guided brachytherapy for treatment of confined prostate cancer. Urology 40:27-32, 1992
13. Blasko JC, Grimm, PD, Ragde H: Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 3:240-249, 1993
14. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 152:1831-1836, 1994
15. Catalona WJ, Smith DS: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837-1842, 1994
16. Bagshaw MA, Cox RS, Hancock SL: Control of prostate cancer with radiotherapy: Long-term results. J Urol 152:1781-1785, 1994
17. Bagshaw MA, Ray GR, Cox RA: Complications associated with radiotherapy of prostate cancer, in Smith RB, Ehrlich RM (eds): Complications of Urologic Surgery: Prevention and Management (ed 2). Philadelphia, PA, Saunders, 1990, pp 88-99
18. Talcott JA, Rieker P, Propert K, et al: Complications of treatment for early prostate cancer: A prospective, multi-institutional outcomes study. Proc Am Soc Clin Oncol 13:A711, 1994 (abstr)
19. Liebel SA, Zelefsky MJ, Kutcher GJ, et al: Three-dimensional conformai radiation therapy in localized carcinoma of the prostate: Interim report of phase 1 dose escalation study. J Urol 152:1792-1798, 1994
20. Shipley WU, Zietman AL, Hanks GE, et al: Treatment related sequela following external beam radiation therapy for prostate cancer: Review with update in patients with stages T1 and T2 tumor. J Urol 152:1799-1805, 1994
21. Zietman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome: J Urol 151:640-645, 1994
22. Zagars GK: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 152:1786-1791, 1994
23. Roy JN, Wallner KE, Chiu-Tsao S, et al: CT-based optimized planning for transperineal prostate implant with customized template. Int J Radiat Oncol Biol Phys 21:483-489, 1991
24. McNeal JE, Redwine EA, Freiha FS, et al: Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12:897-906, 1988
25. Roy JN, Wallner KE, Harrington PJ, et al: A CT-based evaluation method for permanent implants: Application to prostate. Int J Radiat Oncol Biol Phys 26:163-169, 1993
26. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3582-3593, 1993
27. Rosen MA, Goldstone L, Lapin S, et al: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148:331-337, 1992
28. D'Amico AV, Whittington R, Malkowicz SB, et al: A multi-variable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 30:293-302, 1994
29. Oesterling JE, Suman VJ, Zincke H, et al: PSA-detected (clinical stage T1c or B0) prostate cancer. Urol Clin North Am 20:687-693, 1993
30. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994
31. Partin AW, Yoo J, Carter HB, et al: Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993. Letter to the editor. J Urol 152:172-173, 1994
32. Partin AW, Yoo J, Carter HB, et al: Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993. Letter to the editor. J Urol 152:172-173, 1994
33. Smith DS, Catalona WJ: Nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152:1732-1736, 1994
34. Hanks GE, Hanlon A, Schultheiss T, et al: Early prostate cancer: National results of radiation treatment from patterns of care and Radiation Therapy Oncology Group studies with prospects for improvement with conformai radiation and adjuvant androgen deprivation. J Urol 152:1775-1780, 1994
35. Steele Jr GD, Osteen RT, Winchester DP, et al: Clinical highlights from the national cancer data base: 1994. CA 44:71-80, 1994
36. Catalona WJ, Dresner SM: Nerve-sparing radical prostatectomy: Extraprostatic tumor extension and preservation of erectile function. J Urol 134:1149-1153, 1985